Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Global phase 3 study of donanemab in early symptomatic Alzheimer's disease
CTR20222199Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing Donanemab with Placebo (2 arms). Primary endpoint: Change from baseline in integrated Alzheimer's Disease Rating Scale (iADRS). Started Dec 2022; status: active.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on CTR20222199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222199.